Vanda Pharmaceuticals (NASDAQ: VNDA) Rejects Cycle Pharma’s Second Takeover Offer
On Monday, Vanda Pharmaceuticals (NASDAQ: VNDA) rejected UK-based Cycle Pharmaceuticals’ second takeover proposal, which values the drugmaker at $8 per […]
Vanda Pharmaceuticals (NASDAQ: VNDA) Rejects Cycle Pharma’s Second Takeover Offer Read More »